Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: A case report

Hiroki Oikawa, Chihaya Maesawa, Ryo Sato, Kanta Oikawa, Hiroyuki Yamada, Seizo Oriso, Sadahide Ono, Akiko Yashima-Abo, Koji Kotani, Kazuyuki Suzuki, Tomoyuki Masuda

Hiroki Oikawa, Chihaya Maesawa, Kanta Oikawa, Akiko Yashima-Abo, Koji Kotani, Tomoyuki Masuda, Department of Pathology, Iwate Medical University School of Medicine, Morioka, Japan
Ryo Sato, Kazuyuki Suzuki, Department of Internal Medicine I, Iwate Medical University School of Medicine, Morioka, Japan
Hiroyuki Yamada, Seizo Oriso, Department of Internal Medicine, Iwate Prefectural Ninohe Hospital, Ninohe, Japan
Sadahide Ono, Department of Pathology, Iwate Prefectural Central Hospital, Morioka, Japan

Supported by Grants-in-Aid No. 16590289, 16790211 and 16790212, and “Open Research Center” Project for Private Universities: Matching fund Subsidy (2004-2008), from Ministry of Education, Culture, Sports, Science and Technology, Japan
Correspondence to: Dr. Chihaya Maesawa, Department of Pathology, Iwate Medical University School of Medicine, Uchimaru 19-1, Morioka 020-8505, Japan. chihaya@iwate-med.ac.jp
Telephone: +81-19-651-5111 Fax: +81-19-629-9340
Received: 2005-01-18 Accepted: 2005-04-09

Abstract
The anti-arrhythmic agent amiodarone (AD) is associated with numerous adverse effects, but serious liver disease is rare. The improved safety of administration of daily low doses of AD has already been established and this regimen is used for long-term medication. Nevertheless, asymptomatic continuous liver injury by AD may increase the risk of step-wise progression of non-alcoholic fatty liver disease. We present an autopsy case of AD-induced liver cirrhosis in a patient who had been treated with a low dose of AD (200 mg/d) daily for 84 mo. The patient was a 85-year-old male with a history of ischemic heart disease. Seven years after initiation of treatment with AD, he was admitted with cardiac congestion. The total dose of AD was 528 g. Mild elevation of serum aminotransferase and hepatomegaly were present. Liver biopsy specimens revealed cirrhosis, and under electron microscopy numerous lysosomes with electron-dense, whorled, lamellar inclusions characteristic of a secondary phospholipidosis were observed. Initially, withdrawal of AD led to a slight improvement of serum aminotransferase levels, but unfortunately his general condition deteriorated and he died from complications of pneumonia and renal failure. Long-term administration of daily low doses of AD carries the risk of progression to irreversible liver injury. Therefore, periodic examination of liver function and/or liver biopsy is required for the management of patients receiving long-term treatment with AD.

Key words: Amiodarone; Liver cirrhosis; NASH; NAFLD; Liver biopsy

Oikawa H, Maesawa C, Sato R, Oikawa K, Yamada H, Oriso S, Ono S, Yashima-Abo A, Kotani K, Suzuki K, Masuda T. Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: A case report. World J Gastroenterol 2005; 11(34): 5394-5397
http://www.wjgnet.com/1007-9327/11/5394.asp

INTRODUCTION
Amiodarone (AD) is a cationic, amphophilic, iodinated benzofuran derivative primarily used for the treatment of refractory ventricular tachyarrhythmias[1]. Although AD has been used since 1962, it causes various side effects affecting the lung, thyroid gland, cornea, peripheral nerves, and liver[2-3]. In early clinical trials, higher maintenance doses of AD (300-800 mg/d) caused serious side effects in the first year of therapy, and these patients required drug withdrawal[4-6]. In the last two decades, several investigators have shown that daily lower doses of AD (<200 mg/d) are better tolerated but still possess appreciable efficacy in serious cardiac arrhythmias[4-6].

The hepatotoxicity associated with AD is manifested as an asymptomatic and transient elevation of serum aminotransferase[2,3,6-8]. Fortunately, the vast majority of these events are reversible after discontinuation of the medication[2,3,4]. The safer schedule of administration of low doses daily may contribute to reducing the incidence of serious hepatic adverse effects. The histologic appearance of AD-induced liver disease shares several features with that of alcoholic hepatitis. Asymptomatic continuous liver injury by AD may increase the risk of step-wise progression of non-alcoholic fatty liver disease (NAFLD)[7-9]. This implies that severe morphological alterations of the liver may coexist with very mild symptoms in patients receiving long-term treatment with daily low doses of AD. We present herein an autopsy case of AD-induced liver cirrhosis in a patient treated with a low dose of AD daily for 84 mo. We discuss the risk of progression to irreversible liver injury during administration of AD and the value of liver biopsy for patients receiving long-term treatment with a low dose of AD daily.

CASE REPORT
A 85-year-old male with a history of ischemic heart disease...
was being treated with AD for continuing symptomatic ventricular arrhythmias. He was admitted with cardiac congestion in December 2001, 7 years after administration of AD had begun. There was no history of alcohol abuse, obesity or diabetes mellitus. Serological screening and PCR examination for hepatitis viruses were all negative. There were no signs of autoimmune hepatitis. His initial dose of AD was 400 mg daily for 17 d, which was then reduced to a maintenance dose of 200 mg daily. The patient had received continuous medication with AD for 84 mo. On physical examination, corneal opacities were found. No skin discoloration or neuronal symptoms were seen.

Serum total bilirubin was 1.2 mg/dL, aspartate aminotransferase 81 IU/L, alanine aminotransferase 35 IU/L, alkaline phosphatase 452 IU/L, gamma-glutamyl transpeptidase 210 IU/L, lactate dehydrogenase 848 IU/L, and prothrombin time activity 59%. Up to that time, no elevation of serum aminotransferase or signs suggesting liver dysfunction had been observed.

The chest radiograph revealed cardiac enlargement and bilateral pleural effusion without findings of interstitial fibrosis. Abdominal ultrasonography showed enlargement of the left lobe of the liver relative to atrophy of the right lobe, and an irregular liver surface. In addition, ascites and mild splenomegaly were seen. An unenhanced computed tomography (CT) scan of the upper abdomen showed an abnormally high density of liver tissue [111.8 Hounsfield units (HU); normal range 30-70 HU] (Figure 1). A percutaneous liver biopsy examination revealed micronodular cirrhosis accompanied by findings of alcoholic liver disease (Figure 2). Fibrous septa containing proliferating bile ductules and neutrophil polymorphs connected adjacent portal areas (Figure 2). Scattered foci of hepatocellular necrosis with neutrophilic infiltration were observed (Figure 2). Electron microscopic observations showed that hepatocytes contained numerous lysosomes with electron-dense, whorled, lamellar inclusions (LI), characteristic of a secondary phospholipidosis (Figure 3). The findings of the CT scan and the liver biopsy indicated that AD-induced liver cirrhosis was responsible for the hepatotoxicity and his poor general condition. Administration of AD was discontinued. The total dose of AD administered over the 84 mo was 528 g.

Initially, withdrawal of AD led to a slight improvement in the serum aminotransferase level and the ascites. The CT density of the liver decreased to 97.2 HU in February 2002, whereas no significant improvement was observed in the size of the liver. Unfortunately, his general condition deteriorated as a result of complications of pneumonia and renal failure. He died in April 2002.

Autopsy was performed on April 22nd, 2002. Microscopically, features affected by AD were observed in the follicular epithelial cells of the thyroid gland and in the liver. Notably, there were no histological findings suggesting AD-induced pulmonary toxicity, which is more common and often more serious than hepatotoxicity, whereas both his lungs revealed congestion with pneumonic foci.

We compared the light-microscopic and electron-microscopic findings for the biopsy (December 2001) and autopsy (April 2002) materials (Table 1). Light microscopy of the autopsy materials also revealed micronodular cirrhosis. The biopsy material showed both microvesicular and macrovesicular steatosis, but the autopsy material showed only microvesicular steatosis. The number of hepatocytes with Mallory bodies was similar to that of the biopsy specimen. We counted the number of lysosomes

---

**Figure 1** An unenhanced computed tomography (CT) scan of the upper abdomen. The liver has a greatly increased density (111.8 HU).

**Figure 2** Microscopic features of the liver biopsy specimen. A: Micronodular cirrhosis has become established (silver impregnation, scale bar = 200 µm); B: Low power view of the liver biopsy specimen (hematoxylin and eosin stain, scale bar = 200 µm). Fatty degeneration and marked fibrosis with inflammatory cell infiltration were observed; C: High power view of the liver biopsy specimen (hematoxylin and eosin stain, scale bar = 20 µm). Foci of hepatocellular necrosis and dense fibrosis with neutrophilic infiltration were observed. Hepatocytes showed both the microvesicular and macrovesicular types of steatosis.

**Figure 3** Transmission electron micrograph of the biopsy specimen with lamellated inclusions in the cytoplasm of the hepatocyte (original magnification x20 000).
with LI relative to the total number of lysosomes in the liver. The incidence was relatively lower in the autopsy specimen compared with the biopsy specimen (Table 1). Unfortunately, we could not assess the tissue concentration of AD.

### DISCUSSION

The true incidence of AD-induced liver cirrhosis is obscure, since liver biopsy has not been performed routinely in AD-treated patients. Almost all cases of AD-induced liver cirrhosis have been reported in patients receiving higher maintenance doses[15,16], and only five cases arising from administration of daily low doses have been described in the literature (Table 2)[12-14,18,19]. Some investigators have speculated that the total cumulative dose might be more important in estimating the risk of irreversible liver injury[20,21]. The cumulative doses of the patients previously reported ranged from 165 to 213 g, with a duration of treatment of 12-48 mo. The present patient had been treated with 200 mg of AD daily for 84 mo, with a total cumulative dose of 528 g. Even though this dosage is greater than that in previous reports, hepatic abnormalities were not detected during the course of treatment. As asymptomatic progression of liver disease might occur more frequently in patients receiving long-term treatment with AD, periodic examination of liver function and/or biopsy as an early indicator might be helpful to warn off irreversible liver damage. We speculate that the total cumulative dose might be more important in determining the risk of progression of NAFLD in patients receiving long-term treatment with AD. It is well known that steatosis and non-alcoholic steatohepatitis (NASH) can be induced by drugs such as tamoxifen, some anti-retroviral agents and AD[20-22]. These drugs inhibit the mitochondrial β-oxidation of fatty acids (causing steatosis) and respiratory链 of reactive oxygen species (ROS). In hepatocytes, ROS and lipid peroxidation products further impair the respiratory chain, either directly or indirectly through oxidative damage to the mitochondrial genome. Mitochondrial dysfunction can also lead to apoptosis or necrosis, depending on the energy status of the cell. ROS and lipid peroxidation products also activate stellate cells, thus resulting in fibrosis. Finally, ROS and lipid peroxidation increase the generation of several cytokines (TNF-α, TGF-β, and Fas ligand) that play various roles in the pathogenesis of drug-induced NASH[23,24].

Some investigators have postulated that in insulin resistance the combination of elevated plasma concentrations of glucose and fatty acids promotes hepatic fatty acid synthesis and impairs oxidation, leading to hepatic steatosis[25-29]. Several polymorphisms in genes related to insulin resistance appear to be associated with the severity of steatosis[25-29]. We examined a few polymorphisms in the TNF-α, HFE, CYP2E1, and IL-10 genes, but the susceptibility alleles were not present in the patient (data not shown). However, we are now undertaking a genome-wide single nucleotide polymorphism study in patients with drug-induced NASH[28]. Further, several experimental and clinical studies suggest that a number of drugs could be useful for the prevention and/or treatment of NASH. These genetic and clinical approaches may help increase the safety of the long-term administration of AD.

### REFERENCES

1. Mason JW. Amiodarone. N Engl J Med 1987; 316: 455-466
2. Kowey PR, Friedling TD, Marinheca RA, Sulpizzi AM, Stohler JL. Safety and efficacy of amiodarone. The low-dose perspective. Chest 1988; 93: 54-59
3. Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M. Long-term efficacy and toxicity of high- and low-dose amiodarone regimens. J Clin Pharmacol 1989; 29: 418-423
4. Nicklas JM, McKenna WJ, Stewart RA, Mickelson JK, Das SK, Schork MA, Krikler SJ, Quain LA, Morady F, Pitt B. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122: 1016-1021
5. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82
6. Vorperian VR, Navighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30: 791-798
7. Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984; 311: 167-172
8. Poucell S, Irotun J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J, Blendis L, Phillips MJ. Amiodarone-associated N Engl J Med 1987; 316: 455-466.

### Table 1: Comparison of CT density and light and electron microscopic findings between biopsy and autopsy specimens of the liver

| No | Reference | Age (yr) | Duration (mo) | Cumulative dose (g) | Outcome |
|----|-----------|----------|---------------|---------------------|---------|
| 1  | Present case | 85       | 84            | 528                 | Dead    |
| 2  | 12         | 76       | 48            | Not described       | Dead    |
| 3  | 13         | 68       | 13.5          | 165                 | Dead    |
| 4  | 14         | 77       | 12            | 202                 | Dead    |
| 5  | 18         | 79       | 33            | 200                 | Dead    |
| 6  | 19         | 83       | 35            | 213                 | Non-fatal |

Counts were performed of 10 fields (<18 000) of five blocks for each material.
phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984; 86: 926-936

9 Gilinsky NH, Briscoe GW, Kuo CS. Fatal amiodarone hepatotoxicity. Am J Gastroenterol 1988; 83: 161-163

10 Bach N, Schultz BL, Cohen LB, Squire A, Gordon R, Thung SN, Schaffner F. Amiodarone hepatotoxicity: progression from steatosis to cirrhosis. Mt Sinai J Med 1989; 56: 293-296

11 Harrison RF, Elias E. Amiodarone-associated cirrhosis with hepatic and lymph node granulomas. Histopathology 1993; 22: 80-82

12 Tordjman K, Katz I, Bursztyn M, Rosenthal T. Amiodarone and the liver. Ann Intern Med 1985; 102: 411-412

13 Rinder HM, Love JC, Wexler R. Amiodarone hepatotoxicity. N Engl J Med 1986; 314: 318-319

14 Flaharty KK, Chase SL, Yaghsezian HM, Rubin R. Hepatotoxicity associated with amiodarone therapy. Pharmacotherapy 1989; 9: 39-44

15 Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, Seeff LB, Zimmerman HJ. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9: 679-685

16 Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse RM, Rusnock EJ, Wolke A, Benjamin SB, Seeff LB. Histo-pathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990; 21: 59-67

17 Babany G, Mallat A, Zafrani ES, Saint-Marc Girardin MF, Carcone B, Dhumexaux D. Chronic liver disease after long term doses of amiodarone. Report of three cases. J Hepatol 1986; 3: 228-232

18 Singhal A, Ghosh P, Khan AM. Low dose amiodarone causing pseudo-alcoholic cirrhosis. Age Ageing 2003; 32: 224-225

19 Guigui B, Perrot S, Berry JP, Fleury-Feith J, Martin N, Metreau JM, Dhumexaux D, Zafrani ES. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 1988; 8: 1063-1068

20 Fromenty B, Robin MA, Igojulji A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30: 121-138

21 Fromenty B, Fisch C, Labbe G, Deschamps D, Berson A, Letteron P, Pessayre D. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990; 255: 1371-1376

22 Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003; 38: 133-140

23 Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353

24 Day CP. The potential role of genes in nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 673-691

25 Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22: 185-194

26 Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S. Tumor necrosis factor alpha promotor polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-280

27 George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NJ, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318

28 Vidali M, Stewart SF, Rolla R, Daly AK, Chen Y, Mottaran E, Clothier D, Leathart JB, Day CP, Albano E. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003; 37: 410-419

29 Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000; 46: 540-545